OTCMKTS:SGIOY Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free SGIOY Stock Alerts $11.91 +0.04 (+0.34%) (As of 04:29 PM ET) Add Compare Share Share Today's Range$11.49▼$11.9150-Day Range$11.43▼$13.4452-Week Range$10.10▼$13.67Volume39,427 shsAverage Volume63,924 shsMarket Capitalization$14.13 billionP/E Ratio12.67Dividend Yield1.43%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get Shionogi & Co., Ltd. alerts: Email Address Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOY)Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.Read More SGIOY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGIOY Stock News HeadlinesMay 8, 2024 | msn.comTeva hits a five-year high on schizophrenia trial win, Q1 beatMarch 18, 2024 | seekingalpha.comSGIOY Shionogi & Co., Ltd.May 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.February 15, 2024 | wsj.comShionogi & Co. Ltd. ADRFebruary 1, 2024 | uk.investing.comShionogi & Co., Ltd. (4507)February 1, 2024 | markets.businessinsider.comHere's what to expect from Shionogi's earningsFebruary 1, 2024 | msn.comShionogi & Co. GAAP EPS of ¥435.74, revenue of ¥336.82BDecember 18, 2023 | msn.comShionogi commences Phase III monovalent Covid-19 vaccine trialMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.December 17, 2023 | msn.comShionogi & Co. - ADR (SGIOY) Price Target Increased by 14.91% to 16.05November 1, 2023 | benzinga.comApnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep DisordersSeptember 9, 2023 | finance.yahoo.comShionogi & Co., Ltd. (SGIOF)September 7, 2023 | finanznachrichten.deShionogi USA: IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious DiseaseAugust 1, 2023 | msn.comDaiichi COVID vaccine endorsed in Japan; Shionogi’s shot declinedJune 26, 2023 | finance.yahoo.comShionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.May 17, 2023 | msn.comShionogi starts clinical trial for its 2nd oral coronavirus drugApril 5, 2023 | marketwatch.comECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir TreatmentFebruary 22, 2023 | yahoo.comShionogi’s Antibiotic, FETCROJA® (cefiderocol), Is Now Available in the NetherlandsJanuary 17, 2023 | nz.finance.yahoo.comShionogi’s Innovative Antibiotic, FETCROJA® (cefiderocol), Is Now Available in NorwayDecember 26, 2022 | finance.yahoo.comShionogi & Co., Ltd. Unsponsored ADR (SGIOY) Upgraded to Buy: Here's WhyNovember 29, 2022 | yahoo.comKaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 DrugNovember 24, 2022 | news.yahoo.comShionogi seeks Japan approval for COVID-19 vaccineNovember 23, 2022 | yahoo.comLeading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in AmsterdamNovember 22, 2022 | finance.yahoo.comJapan Approves First Homegrown Covid-19 Antiviral PillNovember 22, 2022 | news.yahoo.comJapan's Shionogi shares jump after report of COVID drug gaining efficacy approvalNovember 2, 2022 | benzinga.comOrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 DiabetesSeptember 29, 2022 | finance.yahoo.comShionogi & Co., Ltd. (SGIOY)See More Headlines Receive SGIOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings1/31/2024Today5/08/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:SGIOY CUSIPN/A CIK1281721 Webwww.shionogi.co.jp Phone(166) 202-2161FaxN/AEmployees5,680Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.94 Trailing P/E Ratio12.63 Forward P/E Ratio12.76 P/E Growth1.83Net Income$1.37 billion Net Margins36.27% Pretax MarginN/A Return on Equity12.90% Return on Assets11.19% Debt Debt-to-Equity Ratio0.01 Current Ratio5.47 Quick Ratio5.03 Sales & Book Value Annual Sales$3.23 billion Price / Sales4.36 Cash Flow$1.24 per share Price / Cash Flow9.59 Book Value$6.75 per share Price / Book1.76Miscellaneous Outstanding Shares1,186,180,000Free FloatN/AMarket Cap$14.08 billion OptionableNot Optionable Beta0.26 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Isao Teshirogi Ph.D. (Age 65)CEO, President & Representative Director Comp: $1.84MSusumu MitsumoriVice President of Finance & Accounting DepartmentMr. Kazuhiro HatanakaSenior Executive Officer & Senior VP of Administration DivisionMr. Takeshi Shiota Ph.D.Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.Mr. Yoshimasa KyokawaVice President of Corporate Communications & Secretary OfficeYoshihiro FuruyaVice President of General Marketing and Compliance Officer of Corporate GXP Compliance OfficeMr. Kohji Hanasaki Ph.D.Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business DivisionDr. John A. Keller Ph.D. (Age 59)Senior Executive Officer and Senior VP of R&D Supervisory Unit Akira Kato Ph.D.Corporate Officer & President of Shionogi Pharma Co., LtdDr. Ryuichi Kiyama Ph.D.Senior Executive Officer & Senior VP of Corporate Strategy DivisionMore ExecutivesKey CompetitorsSandoz GroupOTCMKTS:SDZNYEurofins ScientificOTCMKTS:ERFSFSysmexOTCMKTS:SSMXYRecordati Industria Chimica e FarmaceuticaOTCMKTS:RCDTFEisaiOTCMKTS:ESALYView All Competitors SGIOY Stock Analysis - Frequently Asked Questions Should I buy or sell Shionogi & Co., Ltd. stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shionogi & Co., Ltd. in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" SGIOY shares. View SGIOY analyst ratings or view top-rated stocks. How have SGIOY shares performed in 2024? Shionogi & Co., Ltd.'s stock was trading at $11.9720 at the beginning of the year. Since then, SGIOY stock has decreased by 0.9% and is now trading at $11.87. View the best growth stocks for 2024 here. Are investors shorting Shionogi & Co., Ltd.? Shionogi & Co., Ltd. saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 14,600 shares, a decline of 42.1% from the March 31st total of 25,200 shares. Based on an average daily volume of 66,800 shares, the short-interest ratio is presently 0.2 days. View Shionogi & Co., Ltd.'s Short Interest. How were Shionogi & Co., Ltd.'s earnings last quarter? Shionogi & Co., Ltd. (OTCMKTS:SGIOY) released its quarterly earnings data on Wednesday, January, 31st. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.33 by $0.11. The company had revenue of $719.72 million for the quarter. Shionogi & Co., Ltd. had a net margin of 36.27% and a trailing twelve-month return on equity of 12.90%. Is Shionogi & Co., Ltd. a good dividend stock? Shionogi & Co., Ltd. (OTCMKTS:SGIOY) pays an annual dividend of $0.17 per share and currently has a dividend yield of 1.45%. The dividend payout ratio is 18.09%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SGIOY will have a dividend payout ratio of 20.73% next year. This indicates that the company will be able to sustain or increase its dividend. How do I buy shares of Shionogi & Co., Ltd.? Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SGIOY) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shionogi & Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
